Non-alcoholic steatohepatitis

17 trials 3 recruiting MedDRA PT
17 Registered trials
3 Recruiting
11 Unique sponsors
8 Unique IMPs
15 Commercial trials
Drug classes (ATC)
— ATC code not specified 14
N Neurology/Psychiatry (ATC N) 2
A Gastroenterology (ATC A) 2
Mechanism of action (INN-stem analysis)
Unknown / small molecule 6 substances
Erythropoietin analogue 1 substance
GLP-1 receptor agonist 1 substance
Phase III: 5 Phase II: 6 Phase IV: 1 Phase I: 2 Phase I (Other): 4

Filter these 17 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 17 trials

Phase III

5 trials
  • Akero Therapeutics Inc. Commercial
    EFRUXIFERMIN
    2023-505141-48-00 5 countries 2024 n=244
    Recruiting
  • Akero Therapeutics Inc. Commercial
    EFRUXIFERMIN
    2024-512895-36-00 5 countries 2024 n=179
    Recruiting
  • Inventiva Commercial
    LANIFIBRANOR
    2023-508248-23-00 11 countries 2021 n=236
    Ended
  • Madrigal Pharmaceuticals Inc. Commercial
    RESMETIROM
    2024-510626-89-00 8 countries 2019 n=444
    Ended
  • Novo Nordisk A/S Commercial
    SEMAGLUTIDE
    2023-506962-30-00 18 countries 2021 n=219
    Ended

Phase II

6 trials
  • AstraZeneca AB Commercial
    AZD2693 SODIUM
    2023-509704-14-00 3 countries 2023 n=11
    Ended
  • Can-Fite Biopharma Ltd. Commercial
    NAMODENOSON
    2023-510548-19-00 3 countries 2023 n=90
    Recruiting
  • Merck Sharp & Dohme LLC Commercial
    EFINOPEGDUTIDE
    2022-502647-35-00 8 countries 2023 n=67
    Ended
  • Merck Sharp & Dohme LLC Commercial
    EFINOPEGDUTIDE
    2024-510923-20-00 2 countries 2024 n=24
    Ended
  • Mikrobiomik Healthcare Company S.L. Commercial
    ALLOGENEIC FAECAL MICROBIOTA, POOLED
    2022-500185-94-01 1 country n=1
    Pending
  • Mikrobiomik Healthcare Company S.L. Academic
    ALLOGENEIC FAECAL MICROBIOTA, POOLED
    2022-500185-94-00 1 country n=96
    Expired

Phase IV

1 trial
  • Region Midtjylland Academic
    SEMAGLUTIDE
    2023-506300-12-00 1 country 2023 n=24
    Ended

Phase I

2 trials
  • Merck Sharp & Dohme LLC Commercial
    IMP not specified
    2023-505138-88-00 1 country 2023 n=36
    Ended
  • Novo Nordisk A/S Commercial
    IMP not specified
    2023-503595-24-00 1 country 2023 n=30
    Ended

Phase I (Other)

4 trials
  • CCDRD Cooperative Clinical Drug Research and Development AG Commercial
    IMP not specified
    2023-507445-28-00 1 country 2024 n=16
    Ended
  • Dr. Falk Pharma GmbH Commercial
    IMP not specified
    2023-505862-27-00 1 country 2023 n=48
    Ended
  • Merck Sharp & Dohme LLC Commercial
    IMP not specified
    2023-508982-34-00 1 country 2024 n=44
    Ended
  • Dr. Falk Pharma GmbH Academic
    IMP not specified
    2023-505862-27-00 1 country 2023 n=48
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Merck Sharp & Dohme LLC Commercial 4 Phase I, Phase I (Other), Phase II 0
Novo Nordisk A/S Commercial 2 Phase I, Phase III 0
Dr. Falk Pharma GmbH Commercial 2 Phase I (Other) 0
Mikrobiomik Healthcare Company S.L. Commercial 2 Phase II 0
Akero Therapeutics Inc. Commercial 2 Phase III 2
CCDRD Cooperative Clinical Drug Research and Development AG Commercial 1 Phase I (Other) 0
AstraZeneca AB Commercial 1 Phase II 0
Can-Fite Biopharma Ltd. Commercial 1 Phase II 1
Inventiva Commercial 1 Phase III 0
Madrigal Pharmaceuticals Inc. Commercial 1 Phase III 0
Region Midtjylland Academic 1 Phase IV 0
New trials by year
2019
1
2021
2
2023
8
2024
5
← All indication landscapes